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Objective: Bezafibrate is the second generation of fibrate groups used as the drug of choice in the treatment of hyperlipidemia. The purpose of this 
study is to obtained a validated method for analyzing bezafibrate in urine using solid phase extraction (SPE)-High performance liquid 
chromatography (HPLC). 
ABSTRACT 
Methods: Solid phase extraction (SPE) using hydrophilic-lipophilic balance (HLB) cartridge was performed for bezafibrate extraction from urine, 
afterward, a validation of analysis method using high-performance liquid chromatography (HPLC)-(UV) detection was conducted to parameters, 
including: selectivity (Rs), linearity (r), accuracy, precision, limit of detection (LOD) and limit of quantification (LOQ).  
Results: Recovery extraction using SPE resulted %recovery 85-110%. The analysis was performed by high-performance liquid chromatography 
using reversed phase, C18 octadecylsilane (ODS) columns 250 x 26 mm, particle size 10 μl, with the composition of 0.01 M acetate buffer with pH 
3.55: with percent composition (45:55) and 0.8 ml/minute on 230 nm UV detection. Validation includes selectivity, linearity, accuracy, precision 
LOD, and LOQ have fulfilled requirement value.  
Conclusion: The result of recovery extraction using SPE and validation of method exhibited the values that fulfilled the requirements and can be 
used for analysis bezafibrate in the urine. 
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Hyperlipidemia is a global problem that is facing today, this is due to 
changes in lifestyle that occurs [1]. Bezafibrate (2-[4-2-[4chloro-
benzamido]-ethyl phenoxy]-2methylpropanoic acid) is a derivative 
of a known fibrate compound as a class of lipid-lowering drugs that 
is often prescribed [2]. The mechanism of decreasing lipid levels by 
bezafibrate is by increasing the release of triglycerides, cholesterol, 
low-density lipoprotein and raising the amount of high-density 
lipoprotein, bezafibrate works as a peroxisome proliferation 
activated receptor agonist (PPARs) [3]. Bezafibrate is expressed 
about 95% by urine in the form of unchanged bezafibrate [4]. 
Drugs or metabolite analysis in urine or plasma commonly used HPLC-
UV method to reach good result [5, 6]. Studies that have been 
performed for bezafibrate analysis include: bezafibrate in plasma and 
urine using HPLC, where plasma bezafibrate is extracted with diethyl 
ether first, while bezafibrate in urine is directly analyzed after being 
diluted by mobile phase, its time consuming and resulted low accuracy 
[7] bezafibrate in human plasma applied in tablet dispersion system 
by HPLC method [8, 9] bezafibrate in pharmaceutical preparations by 
polarography method [8] bezafibrate in rat serum with Ag-Nitrate 
using HPLC method [10] but, the procedure of drug or metabolite 
isolation is complicated; bezafibrate in a pharmaceutical formulation 
of the HPLC method [1] especially just for high doses. Until now has 
not been reported an analysis of bezafibrate in biological fluids with 
SPE by UV detector. HPLC is a good method for analysis in biological 
fluids because it has good selectivity and sensitivity values and SPE is a 
method that excellent in the extraction of compounds with small levels 
and in a complex matrix [11, 12]. In this work, we attempt to get the 
simple, rapid and accurate of bezafibrate analysis method in human 
urine using SPE-HPLC-UV detector. 
MATERIALS AND METHODS 
Materials 
Bezafibrate (Bezalip Purity >98% purchased from PT Rajawali 
Nusindo), acetonitrile HPLC grade (JT Baker), methanol pro analysis 
(Merck), sodium acetate (Bratachem), acetic acid glacial 
(Bratachem), aquabidestillata (IKA). 
Equipment 
A set of HPLC (Shimadzu LC-10 ATVP) equipped with SPD UV-Vis 
detector) ODS column (Phenomenex) (length of 250 nm, 4.6 mm 
inner diameter, 10 μm particle size), UV-Vis spectrophotometer 
(Analytical Jena, Specord 200), SPE cartridge HLB 30 mg 1 cc 
(Oasis). pH meter (Ohmeter), ultrasonic bath (NEY 1510). 
Methods 
Preparation of working standard of bezafibrate 
Accurately weigh of 2 g of bezafibrate were dissolved in methanol 
add to 100 ml, obtained standard solution with a concentration of 
about 20.000 μg/ml which was subsequently diluted to 200 μg/ml. 
Determination of molar extinction 
Prepare a series of bezafibrate solutions from the stock solution with 
concentrations of 11, 22, and 33 μM. The three solutions were then 
measured their maximum wavelength with the speculator and read 
the absorption of each concentration at the maximum bezafibrate 
wavelength and determined the value of its molar extension. 
Preparation of mobile phase 
Prepared of 0.1 molar acetate buffer with pH 3.5 by dissolving 0.234 
g of sodium acetate up to 300 ml. The solution is stirred using a 
magnetic stirrer. The pH adjustment was performed with the 
addition of glacial acetic acid. Buffer solution then filtered using a 
filter membrane of 0.45 μl, and degassing. A number of acetonitrile 
to be used as a mobile phase are degassed before use. 
Optimization HPLC analysis condition 
To obtain optimum condition, an experiment with various 
concentration of mobile phase of HPLC system to be used is column 
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ODS/C18 (octadecylsilane), length 250 mm, inner diameter 4.6 mm, 
and particle size 10 μm phase of ammonium acetate (0.01 M, pH 3.5, 
regulated by addition of acetic acid): Acetonitrile with optional % 
composition were (35:65, 40:60, and 45:55), flow rate will be set in 
0.8; 0.9; or 1 ml/min at UV Detection 230. The optimum condition is 
stated by reaching a peak resolution (Rs) greater than 1.5 and 
produce fastest in analysis time. 
Optimization of extraction using SPE 
The extraction was done by addition method of bezafibrate in urine 
with a variation of concentration 2,4; 3.8; 4.8; 6.2; and 7.4 μg/ml. 
then extracted with SPE using HLB cartridge. The optimal conditions 
of extraction are expressed when the recovery value of extraction is 
in the range 85-100% 
Validation of analysis method 
Some aspects measured in the validation method are selectivity, 
linearity, precision, accuracy, LOD and LOQ [12]. 
Selectivity 
Selectivity determination is conducted by calculating the value of 
chromatogram resolution (Rs) from the chromatogram.  
Linearity 
While the linearity test obtained from the measurement data of 
standard series solution that has been made five variations of 
concentration 2.4; 3,4; 4.8; 6.2; and 7.8 μg/ml to obtain the 
calibration curve and correlation coefficient (r2
LOD and LOQ 
).  
Measurement of the limit of detection and limit of quantification 
were calculated statistically using linear regression of calibration 
curve [13]. 
Precision 
The repeatability test is performed by injecting of 6 times 
bezafibrate concentration of 4.8 μg/ml in urine in the same day so 
that the data obtained will be expressed as the relative standard 
deviation (% RSD) [13]. 
Accuracy 
The accuracy test was performed by preparing a standard solution 
with 3 and 7 μg/ml of bezafibrate using blank urine, then it was 
analyzed using SPE, both of solution was injected 3 times into the 
HPLC tool in optimum condition. The accuracy value is expressed as 
(%) recovery [13].  
RESULTS AND DISCUSSION 
Determination of molar extinction  
The determination of molar extension (ε) results bezafibrate was 
carried out on three concentrations of 11, 22, and 33 μM in methanol 
at a maximum bezafibrate wavelength of 230 nm (table 1). 
 
Table 1: Results of determination of bezafibrate molar extinction in wavelength 230 nm (ε) 
No. Concentration molar (M) Absorbance  Molar exctingtion (ε)(M-1 cm-1) 












X ±SD 22133.33±1020.893 
 Values represent mean±SD, n=3. 
 
The results of bezafibrate molar exctingtion value presented an 
average value of 22133.33 M-1 cm-1. Its value indicates that 
bezafibrate is possible to be detected by UV detector in the HPLC 
system. The minimum value of molar exctingtion that can be 
detected in UV system must be greater than 10.000 M-1 cm-1 
Optimization of HPLC conditions is carried out against the main 
chromatographic parameters of resolution, retention time, and flow 
rate of mobile phases of various compositions. The result of 
optimizing HPLC condition for bezafibrate is as follows: Column: 
LiChroCART C18, particle size 10 μm, column length 250 mm. mobile 
phase: Ammonium Acetate (0.01 M, with pH 3.5): acetonitrile with 
% composition (55:45), at UV detection 254 nm, flow rate: 0.8 
ml/min and injection volume: 10 μl. The Rs value obtained in this 
condition is 1.55 and retention time of bezafibrate is 6 min. Base on 
its result, analysis condition of HPLC was stated as an optimal 
condition. The short retention times (6 minutes) help to improve the 
efficiency of the analysis so that it is more effective than previous 
studies [8, 12]. 
[12]. 
Optimization HPLC condition 
Recovery of extraction 
The result of the extraction result of bezafibrate test (table 2) was 
done with concentration of 2.4 μg/ml, 4.8 μg/ml, and 7.4 μg/ml. The 
variation of the concentration was based on the level of bezafibrate 
secreted into urine ie about 4.8 μg/ml as previously study [8]. 
 
Table 2: Result of recovery extraction 
Replication Concentration bezafibrate 2.4μg/ml Concentration bezafibrate 4.8 μg/ml Concentration bezafibrate 7.4 μg/ml 









X ±SD 89.4138±1.19 92.9503±0.03 97.3179±1.11 
 Values represent mean±SD, n=3. 
 
The result of recovery extraction for the concentration of bezafibrate 
2.4 μg/ml was valued 88.24%, bezafibrate with 4.8 μg/ml was 
92.55%, and bezafibrate with 7.8 μg/ml equal to 97.01% 
respectively. Based on the results of the analysis, the % recovery of 
the three bezafibrate sample concentrations is eligible because the 
value is in the range of 80-120% [7, 13–15]. SPE method is very 
effective to trace analysis in a biological fluid. It is the recovery of 
extraction can be reach up to 99%. Its value higher than liquid-liquid 
extraction as previously studies that only reach 80-85% [3, 7]. 
Validation of analysis method 
Validation of the analysis method includes parameter selectivity, 
linearity, accuracy, precision, LOD, LOQ, and system suitability test. 
Selectivity 
The selectivity test is performed by calculating the resolution value 
of the peak of the sample chromatogram and the other peak of the 
separate chromatogram (not overlapping). 
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Fig. 1: Chromatogram for resolution of peak 
 
The Rs value (fig. 1) obtained from the analysis is 1.55. Its 
represents the good separation peaks on chromatograms between 
bezafibrate and impurity metabolites (extracted body metabolites).  
The standard of resolution value allowed is greater than 1.5 [12], 
this indicates that the resolution value has fulfilled the validation 
requirements. The chromatogram is relatively clean from impurity 
so as not to interfere with the process of bezafibrate quantification. 
Linearity 
The linearity test (fig. 2) is done to find out the response of the 
method of analysis to the variation of the sample concentration in 
the form of a straight-line calibration curve. The parameter used is 
the correlation coefficient (r2) which will state the linear 
relationship of the calibration curve. The calibration curve was made 
by making 5 variations of bezafibrate concentrations in urine. 
Subsequently undergoing extraction step with SPE, at each 
concentration 3 repetitions were performed (n = 3). Then we create a 
linear equation. Based on the calculation of linear line equation, the 
correlation coefficient (r) is 0.997 with the straight-line equation y = 
48019x-11141. The r2
The LOD and LOQ values were obtained from the calculation of 
bezafibrate calibration curve to the area of the chromatogram. The 
equation used is y = 48019x-11141 so that the LOD value to area 
ratio is 0.055 μg/ml and the LOQ to area ratio is 0.184 μg/ml. Base 
on LOD and LOQ value, the method was sensitive enough to detect 
bezafibrate in urine [13]. SPE help the extraction efficiency that it 
will be assisted to increase detection of drug level in the analysis. 
SPE increases the efficiency of extraction so as to help improve drug 
level detection in the analysis [11, 16]. 
 value meets the linearity requirement for the 
valid method of analysis that is>0.995 [12]. This result shows a curve 
of calibration can be used to quantify bezafibrate levels in the urine. 
LOD and LOQ determination 
 
 
Fig. 2: Calibration curve of linearity 
 
Precision 
The precision test is done by measuring the bezafibrate sample of 
4.8 μg/ml concentration using HPLC with repetition 6 times (n =6) 
was presented in table 3. Based on the results of repeatability test, 
the % RSD for the area of the chromatogram is 2.23%. This indicates 
that the results of the repeatability test analysis were good enough 
and fulfilled the valid value, because a requirement RSD value for the 
biological fluid analysis must be less than 10% [13, 17]. 
 
Table 3: Result of precision 
Concentration of bezafibrate (μg/ml) Peak area (n=6) 






X ±SD 220914±4502.55 
RSD % 2.2326 
Values represent mean±SD, n=6. 
 
Accuracy 
Based on the results of the analysis, accuracy value fulfilled the 
validation criteria (fig. 4). Both of the concentration of bezafibrate 
with concentration 3 μg/ml and 7 μg/ml have % recovery 89.398% 
and 94.305% respectively. Percent recovery for accuracy allowed 
for a method of analysis in a biological matrix is 80-120% [13]. The 
method was accurate for bezafibrate quantification. 
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Tabel 4: Result of accuracy 
Replication Nominal concentration 
3 μg/ml 7μg/ml 














X ±SD 2.681±0.203676 6.60±0.040 




Values represent mean±SD, n=3. 
Table 5: System suitability 
Parameters  RSD (%) 
Retention time (n=6) 1.09 
Peak area (n=6) 2.23 
Values represent in RSD (relatif standar deviation), n=6. 
 
System suitability test  
The system suitability test (table 5). Is done to know that the 
system used can run effectively and parameter used is % RSD. Its 
value must be fulfilled requirement that is RSD<10% for biological 
fluids [17]. Base on the value of % RSD, the system was effective 
for running. 
CONCLUSION 
Extraction using SPE yields excellent results with percent recovery 
near 100% and it can be applied to bezafibrate analysis with a very 
small concentration in complicated matrices. The validation 
methods include parameters: selectivity, linearity, LOD, LOQ, 
accuracy, precision, and system suitability, proved that the method 
used has validity as required so it can be used to analyze bezafibrate 
human urine especially for routine analysis.  
ABBREVIATION  
SPE: solid phase extraction, HPLC: high-performance liquid 
chromatography, UV: ultraviolet, HLB: hydrophilic-lipophilic 
balance, LDL: low-density lipoprotein, LOD: limit of detection, LOQ: 
limit of quantification, SD; standard deviation, RSD: relative 
standard deviation, Rs: Resolution, ODS: octadecylsilane 
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